2010 Fiscal Year Final Research Report
Therapeutic benefits of intravenous administration of genetically-engineering mesenchymal stem cells on spinal cord injury
| Project/Area Number |
20591717
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Cerebral neurosurgery
|
|---|
| Research Institution | Sapporo Medical University |
|---|
Principal Investigator |
NONAKA Tadashi Sapporo Medical University, 医学部, 研究員 (60180759)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
HOUKIN Kiyohiro 札幌医科大学, 医学部, 教授 (90229146)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
HONMOU Osamu 札幌医科大学, 神経再生医学講座, 特任教授 (90285007)
|
|---|
| Project Period (FY) |
2008 – 2010
|
| Keywords | 移植・再生医療 / 再生医学 / 神経科学 / 脳・神経 / 発生・分化 |
|---|
| Research Abstract |
Local injection of mesenchymal stem cells (MSCs) derived from bone marrow has been shown to improve functional outcome in spinal cord injury (SCI). Systemic delivery of MSCs results in therapeutic benefits in a number of central nervous system disorders. In the present study we intravenously administered MSCs derived from bone marrow to study their potential therapeutic effect in a contusive SCI model in the rat. Light microscopic examination revealed that cavitation in the contused spinal cords was less in the MSC-treated rats. Functional outcome was greater in the MSC-treated groups than in sham controls with greatest improvement in the earlier post-contusion infusion times. BDNF-hypersecreting MSC enhanced the therapeutic benefits of MSC on SCI. The availability of autologous MSCs in large number and the potential for systemically delivering cells to target lesion areas without neurosurgical intervention suggests the potential utility of intravenous cell delivery as a prospective therapeutic approach in SCI.
|
Research Products
(4 results)
